Youjia Bio and Tangji Medical Announce Strategic Collaboration to Advance Small Nucleic Acid Therapeutics for Metabolic Diseases

YOUJIA BIO has accumulated years of experience in the small nucleic acid drug technology platform, possessing systematic R&D capabilities from sequence design, delivery optimization to candidate screening, and is able to provide full-process technical support for innovative drug development.

Tangji Medical focuses on the research and development and continuous innovation of interventional treatment devices for metabolic diseases in the digestive tract. It is actively expanding its drug research and development capabilities in the field of metabolic disease treatment, gradually introducing biopharmaceutical R&D pipelines to enrich its comprehensive treatment layout in metabolic diseases.

This collaboration will leverage YOUJIA BIO's leading technology in nucleic acid drug development and Tangji Medical's rich clinical resources and deep market understanding in the metabolic disease field, creating a complementary synergy. It will drive the efficient transition of drug development from early discovery to clinical validation, accelerating the implementation of innovative therapies.

Cui Wenhao, founder of YOUJIA BIO, stated: "We are very pleased to collaborate with Tangji Medical. This collaboration marks ourSmall Nucleic Acid TechnologyHas taken another solid step forward in the field of metabolic diseases. We look forward to bringing patients more effective and safer treatment options through the joint efforts of both parties."

Tangji Medical Chairman Zuo Yuxing also stated: "There are still many unmet clinical needs in the field of diabetes treatment. We believe that small nucleic acid drugs, as a new generation of therapeutic approaches, hold tremendous potential. This collaboration with YOUJIA BIO will accelerate our innovation in the pharmaceuticals sector."

In the future, the two parties will carry out in-depth cooperation in drug design, preclinical research, clinical trials, and subsequent commercialization, jointly promoting innovative breakthroughs in small nucleic acid drugs in the field of diabetes treatment.

About YOUJIA BIO

Founded in 2019 by several returned overseas Ph.D.s and industrialization experts, YOUJIA BIO is dedicated to the research and development of small nucleic acid innovative drugs. It has built the SEQUAD full-process development platform and holds more than 30 independent intellectual property rights. The company is located in the Xiaoshan Economic and Technological Development Zone, Hangzhou, with a nearly 1500㎡ R&D laboratory.It is a Hangzhou municipal R&D center, and has been awarded the titles of "Specialized, Precise, Unique, and Innovative Small and Medium-sized Enterprise in Zhejiang Province" and "National High-tech Enterprise". Its product pipeline covers areas such as anti-fibrosis, antiviral, cardiovascular diseases, and metabolic diseases.

About Tangji Medical

Founded in Hangzhou in 2016, it is a national high-tech enterprise. Centering on the "Gastric Bypass Stent System," it has built an innovative platform for treating metabolic diseases (obesity, type 2 diabetes, fatty liver, etc.) through gastrointestinal intervention. The company holds more than 140 domestic and international patents, and its products have received FDA "Breakthrough Device Designation" and are registered in multiple countries.